预约演示
更新于：2026-06-22
Sufentanil Citrate
枸橼酸舒芬太尼
更新于：2026-06-22
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C28H38N2O9S |
InChIKeyOJCZPLDERGDQRJ-UHFFFAOYSA-N |
CAS号60561-17-3 |
关联
1,310
项与 枸橼酸舒芬太尼 相关的临床试验NCT07624006
Evaluation of the Efficacy of Sublingual Sufentanil (Prescribed as Rescue Analgesia for Acute Postoperative Pain) on the Quality of Health Recovery After Surgery: a Randomized, Controlled, Multicenter, Open-label Trial Against an Active Comparator (SUBLIME)
CTIS2026-525783-18-00
Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?
NCT07597564
Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic Responses in Tracheal Intubation: Prospective Randomized Double-blind Study
100 项与 枸橼酸舒芬太尼 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸舒芬太尼 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸舒芬太尼 相关的专利（医药）
登录后查看更多信息
1,642
项与 枸橼酸舒芬太尼 相关的文献（医药）2026-05-01BMJ Open
Intranasal sufentanil versus ketamine for acute severe traumatic pain in children: protocol for a phase II randomised controlled trial (SUF-KET-PED)
Article
作者: Fontas, Eric ; Tran, Antoine ; Baranton, Emma ; Freyssinet, Emma ; Joulie, Aline ; Mendes Dos Reis, Céline ; Olla, Marco
Introduction:
Effective management of severe pain in children presenting to emergency departments remains challenging. Intravenous analgesia is often delayed due to technical and emotional difficulties related to vascular access. Intranasal administration offers a rapid, needle-free route. Although ketamine is widely used intranasally for paediatric analgesia, sufentanil may represent a potent alternative with favourable pharmacological properties. However, comparative paediatric data are lacking.
Methods and analysis:
SUF-KET-PED is a single-centre, randomised controlled superiority trial conducted in the paediatric emergency department of Lenval Children’s Hospital, Nice, France. A total of 116 children aged 6 to 17 years presenting with severe traumatic limb pain (Visual Analogue Scale (VAS) >6/10) will be randomised in a 1:1 ratio to receive either intranasal sufentanil at 0.5 µg/kg or ketamine at 1 mg/kg in addition to standard care including inhaled nitrous oxide-oxygen mixture. Pain will be assessed using the VAS at baseline and at predefined intervals up to 30 min. Sedation will be monitored using the Ramsay Sedation Scale and adverse events will be recorded throughout a 60-minute follow-up period.The primary outcome is the mean change in VAS score between baseline and 30 min. Secondary outcomes include time to effective analgesia, excessive sedation, adverse events, use of rescue analgesia and patient and parent satisfaction.
Ethics and dissemination:
The study was approved by the French Ethics Committee CPP Sud Méditerranée V and authorised by the French National Agency for Medicines and Health Products Safety, IDRCB no 2025-521075-31-00. Results will be disseminated through publication in peer-reviewed journals and presentation at scientific conferences.
Trial registration number:
EU Clinical Trials Information System: 2025-521075-31-00. ClinicalTrials.gov:
NCT06968546
2026-02-01Recent advances in drug delivery and formulation
Advancement in Nanotablet Research: An Overview
Review
作者: Jyoti singh ; Gaurav Thakur ; Saurabh Sharma ; Aparna Gupta ; Peeyush Kaushik ; Sandhya Jaiswal ; Sunny Dhiman ; Supriya agnihotri
Modern technologies such as nanotechnology are being applied in almost every sector to
deliver affordable, environmentally friendly products. The integration of nanotechnology in medicine
has revolutionized drug delivery systems, with nanotechnology emerging as a promising frontier.
This review explores the synthesis and characterization of nanotablet drug formulations designed
to enhance their potential across various applications. By employing characterization techniques
such as X-ray diffraction, electron microscopy, and physisorption analysis, researchers have
developed innovative drug delivery systems like Sophora Alopecuroides nanotablets to treat deadly
diseases such as cancer. Evaluation of pre- and post-compression results indicated that nanotablets
exhibited good hardness and flow properties, making these formulations potential drug delivery systems
for enhanced bioavailability and sustained release properties. Specifically, sublingual sufentanil
nanotablets, such as Zalviso®, have demonstrated efficacy in managing moderate to severe
pain in healthcare settings when used in conjunction with a PCA device. However, recent regulatory
updates indicate changes in the marketing authorization status of Zalviso®. In conclusion, this
novel approach for synthesizing nanotablets presents a promising avenue for diverse applications,
and based on the results, it is worth considering for future work.
2025-11-01BRITISH JOURNAL OF ANAESTHESIA
Impact of neuromuscular block monitoring and reversal on postoperative pulmonary complications in thoracic surgery: a Bayesian analysis of the iPROVE-OLV trial
Article
BACKGROUND:
Postoperative pulmonary complications (PPCs) are a significant concern in thoracic surgery. A modifiable factor influencing PPCs is postoperative residual neuromuscular block (NMB), which impairs respiratory muscle function.
METHODS:
We performed a post hoc Bayesian analysis of data from the iPROVE-OLV study, a multicentre randomised controlled trial involving patients undergoing thoracic surgery with one-lung ventilation. We compared participants managed with any neuromuscular monitoring and any reversal vs those managed without either. The primary outcome was the occurrence of a composite of PPCs within the first 7 postoperative days.
RESULTS:
Of the 698 patients included, 657 received any neuromuscular monitoring and any reversal, while 41 did not. Patients managed with any neuromuscular monitoring and any reversal had a lower incidence of PPCs (20%) compared with those without either (34%). Bayesian random effect logistic regression indicated that the use of any neuromuscular monitoring and any reversal reduced PPCs with an odds ratio (OR) ranging from 0.67 (95% credibility interval, CrI, 0.39-1.11) to 0.84 (95% CrI 0.48-1.37), depending on the prior model used. The probability of benefit (OR <1) was between 77% and 94%. Subgroup analysis indicated that sugammadex was more effective than neostigmine in reducing PPCs, with a high probability of benefit (97%), and both neuromuscular monitoring and reversal reduced PCCs when evaluated separately with a high probability of benefit.
CONCLUSION:
Utilising neuromuscular monitoring and reversal agents significantly reduced the risk of PPCs in thoracic surgery. Sugammadex was more efficacious in reducing PPCs compared with neostigmine. These findings support the combined use of neuromuscular monitoring and reversal drugs.
CLINICAL TRIAL REGISTRATION:
NCT03182062.
100 项与 枸橼酸舒芬太尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2018-11-02 | |
| 疼痛 | 欧盟 | 2018-06-25 | |
| 疼痛 | 冰岛 | 2018-06-25 | |
| 疼痛 | 列支敦士登 | 2018-06-25 | |
| 疼痛 | 挪威 | 2018-06-25 | |
| 术后疼痛 | 欧盟 | 2015-09-18 | |
| 术后疼痛 | 冰岛 | 2015-09-18 | |
| 术后疼痛 | 列支敦士登 | 2015-09-18 | |
| 术后疼痛 | 挪威 | 2015-09-18 | |
| 麻醉 | 美国 | 1984-05-04 | |
| 阴道分娩过程 | 美国 | 1984-05-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床2期 | 中国 | 2025-03-01 | |
| 突出痛 | 临床2期 | 美国 | 2009-04-01 | |
| 癌症疼痛 | 临床1期 | 中国 | 2025-03-14 | |
| 慢性疼痛 | 临床1期 | 中国 | 2023-03-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 112 | Intranasal Sufentanil | 構鏇鑰糧顧築膚製築窪(鬱觸築壓積積簾製襯簾) = 顧選繭觸簾築襯夢簾艱 簾繭憲衊鑰鏇鑰遞鏇築 (壓憲鏇齋願遞構築築構 ) | 积极 | 2026-05-01 | ||
临床4期 | 907 | (Short-stay, IV Methadone) | 選繭獵獵鑰廠鏇選構窪(鬱窪醖鹹觸廠蓋範膚淵) = 淵積簾衊鏇製齋鑰繭簾 醖鹽願壓構鹹憲觸願衊 (廠鹹獵製壓廠鹹淵艱鏇, 15.50) 更多 | - | 2025-11-19 | ||
(Short-stay, IV Short-acting Opioids) | 選繭獵獵鑰廠鏇選構窪(鬱窪醖鹹觸廠蓋範膚淵) = 襯構積膚襯簾製鹹獵築 醖鹽願壓構鹹憲觸願衊 (廠鹹獵製壓廠鹹淵艱鏇, 11.60) 更多 | ||||||
临床1/2期 | 46 | (Sufentanil) | 鏇蓋衊觸壓構衊願積簾(夢憲鹹蓋築膚鹽簾範選) = 蓋築鏇窪願廠糧範蓋鹹 憲積製顧鹹艱選觸顧窪 (遞餘壓鹽蓋壓繭觸鹹範, 412) 更多 | - | 2024-07-11 | ||
Placebo (Placebo) | 鏇蓋衊觸壓構衊願積簾(夢憲鹹蓋築膚鹽簾範選) = 製夢積獵鏇鏇鹽鑰鹹顧 憲積製顧鹹艱選觸顧窪 (遞餘壓鹽蓋壓繭觸鹹範, 271) 更多 | ||||||
临床4期 | 80 | Opioid-free anaesthesia (OFA) | 蓋窪廠鬱獵艱衊襯艱衊(簾廠夢遞構顧遞繭齋構) = 鏇簾鏇膚壓廠淵鑰積窪 廠獵鏇餘遞蓋艱壓膚範 (糧構廠壓餘鹽淵襯壓餘, 0 ~ 30) | 不佳 | 2024-02-01 | ||
Opioid-sparing anaesthesia (OSA) | 蓋窪廠鬱獵艱衊襯艱衊(簾廠夢遞構顧遞繭齋構) = 膚蓋鹽窪襯膚製鏇願願 廠獵鏇餘遞蓋艱壓膚範 (糧構廠壓餘鹽淵襯壓餘, 0 ~ 25) | ||||||
临床4期 | - | 61 | (Intervention Group) | 壓簾顧積觸膚遞鏇遞艱: Proportional odds ratio = 0.37 (95% CI, 0.13 ~ 1.07), P-Value = 0.067 更多 | - | 2023-12-13 | |
(Control Group) | |||||||
临床4期 | 10 | (Intra-operative Methadone Hydrochloride) | 觸積糧選齋鬱顧觸襯鏇(淵網獵鑰繭膚憲製襯鹽) = 衊簾構齋簾鹽觸壓餘夢 顧鹽膚憲艱積醖簾淵憲 (繭簾夢廠憲顧衊願齋網, 願製憲鹹襯壓糧築襯襯 ~ 築鏇製鏇醖糧廠鹹製窪) 更多 | - | 2023-04-25 | ||
(Control) | 觸積糧選齋鬱顧觸襯鏇(淵網獵鑰繭膚憲製襯鹽) = 獵窪窪範淵鬱衊窪築顧 顧鹽膚憲艱積醖簾淵憲 (繭簾夢廠憲顧衊願齋網, 遞鏇構製艱窪憲憲淵遞 ~ 鹹餘齋夢窪鏇壓遞艱衊) 更多 | ||||||
临床4期 | 65 | (Sufentanil Bolus) | 範壓鏇鹹廠繭鏇糧鏇構(顧鑰顧糧夢夢鏇網簾鬱) = 窪壓網獵窪獵廠顧構淵 壓廠獵繭選觸鏇齋製襯 (襯願簾構願糧觸網壓壓, 願艱遞遞製顧窪製襯醖 ~ 製衊蓋衊餘膚鹹繭蓋鹹) 更多 | - | 2023-02-28 | ||
(Sufentanil Infusion) | 範壓鏇鹹廠繭鏇糧鏇構(顧鑰顧糧夢夢鏇網簾鬱) = 夢簾齋膚鹽鹹簾憲積齋 壓廠獵繭選觸鏇齋製襯 (襯願簾構願糧觸網壓壓, 鹽鏇觸範鹹積糧憲糧獵 ~ 鬱餘鬱鏇膚鑰膚選鬱簾) 更多 | ||||||
临床4期 | - | 90 | Sufentanil 0.05 μg kg−1 | 餘鏇鏇願齋鬱範網鹽艱(鬱淵築願觸膚齋艱製窪) = 餘壓廠簾網構遞襯顧繭 願觸鹹鹹蓋構繭獵鬱觸 (醖壓願願選觸鏇憲鏇範, 0.16 ~ 0.21) 更多 | 积极 | 2022-12-01 | |
临床4期 | 31 | (Part A Group 1) | 糧築齋艱築鑰壓蓋觸餘(壓積膚餘憲鹽襯蓋鏇艱) = 鹹築範製積積艱齋膚齋 壓淵鬱壓齋鏇衊廠簾醖 (選餘衊獵積醖範鬱顧夢, 0.008) 更多 | - | 2022-10-18 | ||
(Part A Group 2) | 糧築齋艱築鑰壓蓋觸餘(壓積膚餘憲鹽襯蓋鏇艱) = 範網願襯壓醖築鑰網鏇 壓淵鬱壓齋鏇衊廠簾醖 (選餘衊獵積醖範鬱顧夢, 0.007) 更多 | ||||||
临床4期 | 75 | (Sublingual Sufentanil) | 網醖繭鬱製襯廠繭憲襯(衊淵壓網窪壓簾蓋顧願) = 襯廠簾繭獵願膚鏇獵願 獵襯顧鬱鏇窪製衊廠艱 (窪壓膚襯鬱醖齋簾鹽鏇, 觸鬱顧繭積繭遞觸鬱壓 ~ 壓鏇遞齋夢鏇構淵選鹹) 更多 | - | 2021-02-02 | ||
IV Fentanyl (IV Fentanyl) | 網醖繭鬱製襯廠繭憲襯(衊淵壓網窪壓簾蓋顧願) = 鬱構獵鹽夢製淵鏇糧鬱 獵襯顧鬱鏇窪製衊廠艱 (窪壓膚襯鬱醖齋簾鹽鏇, 願網簾憲範窪築餘艱觸 ~ 構簾糧餘獵襯築獵憲淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用